Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the medical and healthcare services sector is 839,200 yuan [2] - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2] - The top three highest-paid company secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2] Age and Education Distribution - Company secretaries aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1] - The educational background of company secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1] - Among the doctoral degree holders, there are 7 individuals, with the only full-time doctoral company secretary in the industry being Cao Nai'en from Huaxia Eye Hospital [1]

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

和元生物积极可持续发展理念融入公司治理的各项制度和流程，进一步健全和完善公司治理机制。公司通过优化治理结构、强化风险防控、提升决策科学性 等措施，推动实现可持续发展，努力实现企业价值与社会价值的共同提升。 和元生物严格遵守《公司法》等法律法规及上海证券交易所科创板上市规则，建立了科学、规范、高效的公司治理体系。股东大会、董事会、监事会及高级 管理层各司其职、协调运转，确保了公司决策的科学性和执行的有效性。 近日，证券之星第三届ESG新标杆企业评选结果揭晓，和元生物凭借在环境、社会和治理(ESG)领域的卓越实践，荣获"公司治理先锋奖"。该奖项是由证券 之星联合妙盈科技等专业权威机构，在中国首席经济学家论坛等指导下设立的ESG领域权威奖项，旨在挖掘并表彰在环境(如低碳减排、绿色供应链)、社会 (如乡村振兴、公益慈善)及公司治理(如合规管理、风险防控)三大维度实现卓越实践，推动经济效能与社会责任深度融合的企业。 为了更好地开展ESG治理工作，优化ESG管理的顶层设计，和元生物将"董事会战略委员会"更名为"董事会战略与ESG委员会"，设立ESG工作小组，负责对 公司长期发展战略、可持续发展工作进行研究并提出建议，以及 ...

Group 1 - The core viewpoint of the news is that Hongtu Innovation Fund has conducted research on a listed company, He Yuan Biological, focusing on its CRO business and financial projections for 2024 [1] - He Yuan Biological's CRO business primarily provides various services for basic research in cell and gene therapy, with expected revenue of 85.82 million yuan in 2024 [1] - The company has a significant reliance on CDMO services, with an outsourcing penetration rate of 65%, and new CDMO orders exceeding 270 million yuan in 2024 [1] - He Yuan Biological has assisted clients in obtaining 44 IND approvals and is managing over 450 CDMO projects [1] - The company is gradually increasing domestic replacements for key imported equipment and consumables through collaboration with local suppliers [1] - Management expenses for 2024 are projected to be 81.08 million yuan, reflecting a year-on-year increase of 27.48% due to the operation of the Lingang Industrial Base [1] - The accounts receivable aging structure is reasonable, with slightly extended customer payment terms but low bad debt risk [1] - The company plans to maintain a workforce of 692 employees by enhancing productivity through training systems and incentive mechanisms [1] - Shareholder Hua Rui Sheng Yin intends to reduce holdings by no more than 6,490,367 shares, accounting for no more than 1% of the total share capital [1] Group 2 - Hongtu Innovation Fund was established in 2014 and currently has an asset management scale of 18.045 billion yuan, ranking 123 out of 210 [2] - The fund's non-monetary public fund asset management scale is 8.548 billion yuan, ranking 128 out of 210 [2] - The fund manages 39 public funds, ranking 111 out of 210, with 13 public fund managers, ranking 94 out of 210 [2] - The best-performing public fund product in the past year is Hongtu Innovation Medical (002173), with a latest unit net value of 1.55 and a growth of 69.34% over the past year [2]

Core Insights - AbbVie is acquiring Capstan Therapeutics for $2.1 billion to enhance its product line in immunological diseases through mRNA-based CAR-T therapy [2] - Yuan Sheng Bio has made significant advancements in CAR-T technology, including improvements in lentiviral vector technology and the establishment of an mRNA CAR-T electroporation platform [2] Group 1: AbbVie's Acquisition - AbbVie is expanding its capabilities in CAR-T therapy by acquiring Capstan Therapeutics for $2.1 billion [2] - The acquisition aims to strengthen AbbVie's product offerings in the field of immunological diseases [2] Group 2: Yuan Sheng Bio's Technological Advancements - Yuan Sheng Bio has achieved a 90% positive rate in NK cell transduction through optimized lentiviral vector technology [2] - The company has overcome challenges in the production process, enhancing the titer of lentiviral vectors [2] - Yuan Sheng Bio has successfully built an mRNA CAR-T electroporation platform and made breakthroughs in enhanced CAR-T project processes [2] - The company is collaborating strategically to develop advanced mRNA-LNP non-viral vector technologies for in-vivo CAR-T therapies [2] - Yuan Sheng Bio has established a T-Flash short-term autologous CAR-T process and applied it to client IND projects [2] - As of Q1 2025, the company has assisted clients in obtaining multiple IND approvals for various product types, including CAR-T, Treg, and stem cells [2]

Core Viewpoint - The company, He Yuan Biology, is making significant advancements in CAR-T therapy, a cutting-edge cell immunotherapy that modifies patients' T cells to target cancer cells effectively [1] Group 1: Technological Advancements - The company has achieved a 90% positive rate in the transduction of NK cells using optimized lentiviral vector technology, overcoming challenges in the production process [1] - Improvements in CAR-T related lentiviral vector yield have been made through sequence optimization and the replacement of traditional RSV promoters with preferred promoters [1] - The establishment of an mRNA CAR-T electroporation platform has been successfully completed, along with breakthroughs in enhanced CAR-T project processes [1] Group 2: Strategic Collaborations - The company has formed strategic partnerships to develop advanced technologies in in-vivo CAR-T therapies, including mRNA-LNP non-viral vector technologies [1] - Extensive platform technology research and development has led to the establishment of the T-Flash short-term autologous CAR-T process, which is being applied to client IND projects [1] Group 3: Regulatory Achievements - As of Q1 2025, the company has assisted clients in obtaining multiple domestic and international IND approvals for various product types, including CAR-T, Treg, and stem cell therapies [1]

Group 1 - The company held its fourth board meeting on July 22, 2025, to discuss the stock incentive plan [2][3] - The board approved the first grant of restricted stock under the 2025 stock incentive plan, with a grant date of July 22, 2025, at a price of 3.09 yuan per share, granting 2,996,400 shares to 61 eligible participants [3][9] - The decision was made unanimously with all 9 directors present, and the meeting complied with relevant laws and regulations [2][6] Group 2 - The stock incentive plan was previously approved at the third extraordinary shareholders' meeting on July 16, 2025, and the board confirmed that all conditions for the first grant had been met [11][12] - The restricted stock represents approximately 0.46% of the company's total share capital of 649,036,700 shares [14] - The plan allows for the stock to vest over a maximum period of 36 months, with specific vesting conditions [20][25] Group 3 - The board's remuneration and assessment committee verified that the grant conditions were satisfied and that the participants met the eligibility criteria [16][24] - The company will account for the stock incentive plan in accordance with relevant accounting standards, estimating the impact on financial performance [25][26] - Legal opinions confirm that the grant complies with applicable regulations and that necessary approvals have been obtained [28]

Group 1 - The company held its fourth board meeting on July 22, 2025, which was an emergency meeting attended by all nine directors and senior management [1] - The board approved the proposal for the initial grant of restricted stock under the 2025 Restricted Stock Incentive Plan, with a grant date of July 22, 2025, and a grant price of 3.09 yuan per share [1] - A total of 2,996,400 shares of restricted stock will be granted to 61 eligible incentive recipients [1] Group 2 - The proposal was reviewed and approved by the company's Compensation and Assessment Committee during its second meeting [2] - Related directors recused themselves from the voting process, resulting in a vote of 4 in favor, 0 abstentions, and 0 against [2]

和元生物技术（上海）股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制性股票激励 计划首次授予激励对象名单的审核意见(截止授予日) 和元生物技术（上海）股份有限公司（以下简称"公司"）董事会薪酬与考 核委员会依据《中华人民共和国公司法》 （以下简称" 《公司法》"）、 《中华人民共 和国证券法》(以下简称"《证券法》")、 《上市公司股权激励管理办法》(以下 简称"《管理办法》")、 《上海证券交易所科创板股票上市规则》(以下简称"《科 （1）最近12个月内被证券交易所认定为不适当人选； （2）最近12个月内被中国证监会及其派出机构认定为不适当人选； （3）最近12个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 管理人员、核心技术人员、核心业务人员以及董事会认为需要激励的其他人员， 不包括公司独立董事、单独或合计持有公司5%以上股份的股东、公司实际控制人 及其配偶、父母以及外籍员工。 准的本次激励计划中规定的首次授予激 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-056 和元生物技术（上海）股份有限公司 关于向 2025 年限制性股票激励计划激励对象 （一）本次限制性股票授予已履行的决策程序和信息披露情况 司<2025 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2025 年 限制性股票激励计划实施考核管理办法>的议案》《关于公司 2025 年限制性股票 激励计划首次授予的激励对象名单的议案》《关于提请股东会授权董事会办理股 权激励相关事宜的议案》。董事会薪酬与考核委员会对公司 2025 年限制性股票激 励计划（草案）进行了核实，并出具了相关核查意见。2025 年 6 月 28 日，公司 在上海证券交易所网站（www.sse.com.cn）披露了《和元生物技术（上海）股份 有限公司 2025 年限制性股票激励计划（草案）摘要公告》 （公告编号：2025-049）、 首次授予限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 限制性股票首次授予日：2025 年 7 月 22 ...